Clinical trials in allogeneic blood and marrow transplantation (alloBMT) are often developed from observations made using preclinical models. My research focus at the University of Wisconsin has been on using mouse models of alloBMT to optimize therapies that prevent graft-versus-host-disease (GVHD) and maximize graft-versus-tumor (GVT) effects. My background has been in understanding the biology of delayed infusions of T cells, how they cause GVHD pathology and their interactions with antigen presenting cells (APCs) generated from the donor graft. My present research is investigating the role of JAK1/STAT1 signaling on APCs in preventing GVHD, and combining NK cells with immunocytokines to enhance GVT effects against neuroblastoma. In addition, we are developing strategies to monitor T and NK cell trafficking after alloBMT by magnetic resonance imaging.
Christian Capitini, MD
1111 Highland Ave
Madison, WI 53705
Using mouse models of allogeneic blood and marrow transplantation (alloBMT) to optimize therapies that prevent graft-versus-host-disease (GVHD) and maximize graft-versus-tumor (GVT) effects